BRAINBox Solutions

The company's core offering is the BRAINBox TBI test, a multi-modal platform designed to provide an objective assessment of concussion. This system combines data from a panel of proprietary blood-based biomarkers, neurocognitive assessments conducted on a tablet or mobile device, and symptom reporting. An artificial intelligence-driven algorithm analyzes these inputs to generate a single, easy-to-read score. This score is intended to aid clinicians in the diagnosis of mTBI and provide a prognosis regarding the likelihood of a patient experiencing ongoing symptoms. The test can be deployed in various settings, including emergency departments, urgent care centers, and clinical laboratories. The U.S. Food and Drug Administration (FDA) granted the BRAINBox TBI test a Breakthrough Device Designation in June 2019, a program designed to expedite the development and review of medical devices that offer more effective treatment or diagnosis for life-threatening or debilitating conditions.

BRAINBox Solutions serves the healthcare sector, specifically targeting emergency medicine and urgent care where rapid and accurate TBI diagnosis is critical. The business model appears to be centered on the sale of its diagnostic and prognostic testing system to healthcare providers. The company is actively engaged in clinical trials to support regulatory submissions for marketing approval in the U.S. and internationally. Its HeadSMART II pivotal trial has enrolled thousands of subjects to validate the test in adults. Additionally, BRAINBox is developing specialized versions of the test for pediatric and geriatric populations, supported in part by grants from the National Institutes of Health (NIH). The company has raised significant capital through various funding rounds, including a $23 million Series A in 2020 and a Series B financing round in 2023, with investors like BioVentures Investors, Genoa Ventures, and the Virginia Innovation Partnership Corporation.